Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11339118 | PMC |
| http://dx.doi.org/10.1002/hsr2.2303 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Facial Botulinum Toxin A Injections in Alleviating Neuropsychiatric Symptoms in Parkinson's Disease Patients: An Open-Label, Nonrandomized Controlled Trial.
Brain Behav
September 2025
Department of Neurology, Huai'an First People's Hospital, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu, China.
Background And Purpose: Parkinson's disease (PD), a prevalent neurodegenerative disorder characterized by motor impairments, frequently accompanied by neuropsychiatric symptoms that significantly impair daily functioning and quality of life. The present study aimed to assess the efficacy of botulinum toxin A (BTX-A) in alleviating neuropsychiatric symptoms among PD patients.
Methods: This is an open-label, nonrandomized controlled trial.
Electrophysiological Evidence of Contralateral Neuromuscular Effects Following Long-Term Botulinum Toxin Therapy in Hemifacial Spasm.
Toxins (Basel)
August 2025
Department of Neurology, Ankara City Hospital, University of Health Sciences, 06000 Ankara, Turkey.
Hemifacial spasm (HFS) is a cranial nerve disorder characterized by involuntary contractions of muscles innervated by the facial nerve. Botulinum toxin type A (BoNT-A) is widely used for symptom control. Although local diffusion is well established, the extent and clinical relevance of BoNT-A spread to contralateral muscles remain unclear.
View Article and Find Full Text PDFRole of Perinasal Musculature in Ipsilateral Nasal Obstruction During Synkinesis Progression.
Facial Plast Surg Aesthet Med
August 2025
Department of Otolaryngology and Division of Facial Plastic and Reconstructive Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Facial synkinesis can lead to unintended activation of perinasal muscles, contributing to dynamic nasal obstruction. To determine whether targeted botulinum toxin injections, compared to no treatment, reduce new ipsilateral nasal obstruction symptoms in patients with facial synkinesis, as measured by patient-reported outcomes and the Nasal Obstruction Symptom Evaluation (NOSE) scale. A retrospective review was conducted of patients presenting with ipsilateral nasal obstruction and synkinesis at a multidisciplinary facial nerve clinic.
View Article and Find Full Text PDFBotulinum Toxin-A, Generating a Hypothesis for Orofacial Pain Therapy.
Toxins (Basel)
August 2025
Department of Oral Medicine, Sedation and Imaging, Hadassah Medical Center, Faculty of Dental Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
Orofacial pain encompasses a spectrum of disorders ranging from musculoskeletal disorders, such as myofascial pain, and temporomandibular disorders to neuropathic situations, such as trigeminal neuralgia and painful post-traumatic trigeminal neuropathy, and neurovascular pain such as orofacial migraine and cluster orofacial pain. Each require tailored prophylactic pharmacotherapy, such as carbamazepine, gabapentin, pregabalin, amitriptyline, metoprolol, and topiramate. Yet a substantial subset of patients remains refractory.
View Article and Find Full Text PDFAre Post-Care Recommendations Following Upper-Face Botulinum Toxin Treatment Scientifically Necessary? A Retrospective Study Based on 5000 Patients.
Toxins (Basel)
July 2025
"Santorelli and Partners", Via Raffaele Morghen, 88, 80129 Napoli, NA, Italy.
Background: Patient care following botulinum toxin injections has long been guided by anecdotal instructions, often based on theoretical considerations. This study evaluates the necessity of extended post-treatment instructions by analyzing outcomes and satisfaction in patients who followed only a 10 min precaution protocol.
Materials And Methods: A retrospective, multicentric study was conducted across six Italian centers, analyzing 5014 patients treated with botulinum toxin for upper facial wrinkles between 2015 and 2020.